MedTrace Logo

Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

NCT01699152 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2019-07-25

No results posted yet for this study

Summary

This is a multi-center, open-label, dose escalation study.

Conditions

Interventions

DRUG

TG02 citrate

TG02 citrate capsules

Sponsors & Collaborators

  • Tragara Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • T Parrott · Tragara Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2015-07-31
Completion
2016-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01699152 on ClinicalTrials.gov